Cancer Therapy Advisor5d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
pharmaceuticalcommerce6d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...